Recall archive / FDA drug enforcement
Rifampin Capsules USP 150mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryl... — FDA record D-0283-2024
Reported terminated
Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.
Source date Jan 5, 2024. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
What the record says
- Product
- Rifampin Capsules USP 150mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-658-06
- Reason
- Subpotent Drug and Failed Impurities/Degradation Specifications
- Classification
- Class II
- Recalling firm
- Lupin Pharmaceuticals Inc.
- Quantity
- 15,576 Bottles
- Agency-reported status
- Terminated
- Source record identifier
- D-0283-2024
What the recall classes mean. Classification is an agency assessment, not individual medical advice.
Lot and product identifiers
| Label field | Details supplied by the agency |
|---|---|
| Lot, code or applicability | A200816 exp 1/2024 A201248 exp 3/2024 |
Match all identifying details in the current notice. A brand name alone is not enough.
Distribution
Product was distributed to 32 Wholesale/distributor accounts who further distributed the product to 156 distribution sites.
No US distribution state could be established from this record. Check the official notice.
Dates in the source
- Report date
- Feb 7, 2024
- Recall initiation date
- Jan 5, 2024
- Center classification date
- Jan 30, 2024
- Termination date
- Aug 27, 2024
FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.